Apr-21-20 Reiterated H.C. Wainwright
Buy
$30 → $33
Aug-12-19 Reiterated H.C. Wainwright
Buy
$31 → $30
May-29-19 Reiterated Laidlaw
Buy
$26 → $32
Feb-06-19 Resumed Jefferies
Buy
$22
Jan-15-19 Initiated BofA/Merrill
Neutral
$19
Sep-21-18 Initiated Cantor Fitzgerald
Overweight
Sep-13-18 Initiated Jefferies
Buy
$30
Aug-08-18 Reiterated Stifel
Buy
$22 → $26
Jun-28-18 Reiterated H.C. Wainwright
Buy
$24 → $26
Mar-12-18 Resumed H.C. Wainwright
Buy
$22
Feb-12-18 Upgrade Janney
Neutral → Buy
Jan-19-18 Initiated Seaport Global Securities
Buy
$27
Jun-30-17 Reiterated Stifel
Buy
$24 → $20
Jun-30-17 Reiterated Laidlaw
Buy
$35 → $30
Jun-30-17 Downgrade Janney
Buy → Neutral
Mar-28-17 Reiterated Laidlaw
Buy
$20 → $35
Mar-28-17 Reiterated H.C. Wainwright
Buy
$22 → $30
Mar-10-17 Reiterated Laidlaw
Buy
$17 → $20
Oct-13-16 Initiated H.C. Wainwright
Buy
$20
Aug-08-16 Reiterated Needham
Buy
$27 → $23
Feb-26-21 08:01AM Feb-25-21 04:01PM 02:30PM Feb-24-21 10:13AM Feb-18-21 04:01PM Feb-10-21 12:38AM Feb-07-21 02:13PM Feb-03-21 03:21AM Jan-11-21 07:00AM Jan-08-21 08:56AM Jan-06-21 07:00AM Dec-28-20 07:00AM Dec-24-20 07:30AM Dec-22-20 04:05PM Dec-18-20 12:19AM Dec-02-20 07:00AM Nov-17-20 01:16PM Nov-12-20 05:42AM Nov-11-20 07:00AM Nov-09-20 09:00PM 05:25PM 04:52PM 04:01PM 02:45PM Nov-02-20 04:01PM Oct-27-20 04:05PM Oct-22-20 12:00PM Oct-21-20 04:01PM Oct-20-20 03:30PM 09:56AM 08:17AM 01:00AM Oct-16-20 11:01AM Oct-14-20 12:57PM Oct-11-20 08:55AM Oct-01-20 07:00AM Aug-27-20 03:37PM 09:55AM Aug-11-20 05:30PM Aug-10-20 06:05PM 04:01PM Aug-06-20 04:01PM Aug-03-20 04:01PM Jul-29-20 12:33PM Jul-13-20 02:47PM Jul-08-20 01:34PM Jun-30-20 07:00AM Jun-25-20 06:04PM Thomson Reuters StreetEvents
Jun-17-20 07:00AM May-27-20 04:01PM May-15-20 11:00AM May-12-20 06:00AM May-11-20 05:55PM 04:01PM May-07-20 07:00AM May-04-20 04:01PM Apr-29-20 07:14AM 07:03AM Apr-28-20 12:34PM Apr-21-20 08:07AM 01:30AM 01:30AM Apr-20-20 09:40AM Apr-08-20 07:00AM Mar-25-20 07:00AM Mar-23-20 06:49AM Thomson Reuters StreetEvents +5.13%
Mar-10-20 01:45PM Feb-29-20 08:05AM Feb-27-20 05:55PM 04:01PM Feb-20-20 04:01PM Feb-03-20 06:12AM Jan-15-20 05:26PM Jan-08-20 04:01PM Dec-19-19 09:32PM Dec-06-19 04:01PM 07:20AM Thomson Reuters StreetEvents
Dec-04-19 10:02AM 07:14AM Dec-03-19 04:01PM 08:41AM 07:35AM 07:00AM Nov-13-19 09:12AM Nov-12-19 04:01PM Nov-11-19 07:00AM Nov-05-19 06:35PM 04:01PM Nov-01-19 07:00AM Oct-29-19 04:40PM 04:01PM 10:32AM Oct-20-19 08:45AM Oct-14-19 07:00AM Oct-01-19 02:23PM Sep-26-19 04:01PM Sep-19-19 10:11AM Aug-21-19 04:24PM 11:44AM 07:04AM
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Terrillion Scott Sec'y; Chief Compliance & G.C. Feb 25 Sale 19.33 4,004 77,397 44,432 Feb 25 09:06 PM Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D Feb 25 Sale 19.33 5,003 96,708 112,677 Feb 25 09:05 PM Goncalves Joana Chief Medical Officer Feb 25 Sale 19.33 3,372 65,181 26,703 Feb 25 09:04 PM CHALMERS DEREK T President & CEO Feb 25 Sale 19.33 11,729 226,722 943,614 Feb 25 09:02 PM Goncalves Joana Chief Medical Officer Feb 22 Sale 19.73 2,000 39,460 26,075 Feb 24 05:02 PM Goncalves Joana Chief Medical Officer Jan 21 Sale 20.12 2,000 40,240 28,075 Jan 25 05:32 PM Terrillion Scott Sec'y; Chief Compliance & G.C. Dec 30 Sale 15.30 1,946 29,774 42,436 Dec 30 06:16 PM Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D Dec 30 Sale 15.30 2,812 43,024 109,680 Dec 30 06:15 PM Goncalves Joana Chief Medical Officer Dec 30 Sale 15.30 1,298 19,859 30,075 Dec 30 06:14 PM CHALMERS DEREK T President & CEO Dec 30 Sale 15.30 6,078 92,993 936,593 Dec 30 06:12 PM CHALMERS DEREK T President & CEO Dec 28 Sale 16.00 5,000 80,000 942,671 Dec 29 06:41 PM Goncalves Joana Chief Medical Officer Dec 21 Sale 15.00 2,000 30,000 27,373 Dec 23 07:11 PM CHALMERS DEREK T President & CEO Dec 16 Sale 14.95 5,000 74,750 928,921 Dec 18 04:58 PM CHALMERS DEREK T President & CEO Dec 10 Sale 15.29 7,500 114,675 933,921 Dec 11 08:32 PM Goncalves Joana Chief Medical Officer Nov 23 Sale 15.31 2,000 30,620 29,373 Nov 25 04:48 PM Posner Christopher Director Nov 19 Sale 15.82 2,000 31,638 11,200 Nov 23 08:28 PM CHALMERS DEREK T President & CEO Nov 17 Sale 16.00 11,799 188,784 941,421 Nov 19 05:29 PM VOGELBAUM MARTIN Director Nov 17 Sale 16.09 6,000 96,540 14,400 Nov 19 05:30 PM Goncalves Joana Chief Medical Officer Nov 10 Sale 15.00 2,000 30,000 31,373 Nov 13 05:39 PM Goncalves Joana Chief Medical Officer Oct 20 Sale 15.00 2,000 30,000 33,373 Oct 22 06:00 PM CHALMERS DEREK T President & CEO Sep 03 Sale 16.00 3,201 51,216 953,220 Sep 08 05:22 PM CHALMERS DEREK T President & CEO Aug 03 Sale 16.42 5,000 82,100 956,421 Aug 05 06:20 PM CHALMERS DEREK T President & CEO Jul 01 Sale 17.11 5,000 85,550 961,421 Jul 02 04:40 PM Goncalves Joana Chief Medical Officer Jun 12 Sale 15.20 10,627 161,530 35,373 Jun 12 06:00 PM CHALMERS DEREK T President & CEO Jun 03 Sale 16.01 4,300 68,843 966,421 Jun 03 07:53 PM Ives Jeffrey L. Director Jun 01 Option Exercise 9.94 1,000 9,940 7,000 Jun 03 07:51 PM CHALMERS DEREK T President & CEO Jun 01 Sale 16.00 700 11,200 970,721 Jun 03 07:53 PM Ives Jeffrey L. Director Jun 01 Sale 16.00 1,000 16,000 6,000 Jun 03 07:51 PM CHALMERS DEREK T President & CEO May 22 Sale 16.00 371 5,936 971,421 May 22 06:26 PM CHALMERS DEREK T President & CEO May 21 Sale 16.00 3,500 56,000 971,792 May 22 06:26 PM CHALMERS DEREK T President & CEO May 20 Sale 16.00 1,200 19,200 975,292 May 22 06:26 PM Ives Jeffrey L. Director May 12 Option Exercise 9.94 2,500 24,850 8,500 May 14 08:02 PM CHALMERS DEREK T President & CEO May 12 Sale 16.00 4,929 78,864 976,492 May 14 08:04 PM Ives Jeffrey L. Director May 12 Sale 16.00 2,500 40,000 6,000 May 14 08:02 PM Ives Jeffrey L. Director Apr 21 Option Exercise 9.94 2,500 24,850 8,500 Apr 21 07:09 PM Terrillion Scott Sec'y; Chief Compliance & G.C. Apr 21 Sale 15.56 2,721 42,339 38,382 Apr 21 06:50 PM Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D Apr 21 Sale 15.58 12,894 200,889 104,492 Apr 21 06:49 PM CHALMERS DEREK T President & CEO Apr 21 Sale 15.56 6,348 98,775 981,421 Apr 21 06:47 PM Ives Jeffrey L. Director Apr 21 Sale 16.00 2,500 40,000 6,000 Apr 21 07:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
